Cargando…

Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells

Hereditary, hormonal, and behavioral factors contribute to the development of breast cancer. Alcohol consumption is a modifiable behavior that is linked to increased breast cancer risks and is associated with the development of hormone-dependent breast cancers as well as disease progression and recu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Candelaria, Nicholes R., Weldon, Ryan, Muthusamy, Selvaraj, Nguyen-Vu, Trang, Addanki, Sridevi, Yoffou, Paule-Helena, Karaboga, Husna, Blessing, Alicia M., Bollu, Lakshmi Reddy, Miranda, Rajesh C., Lin, Chin-Yo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681367/ https://www.ncbi.nlm.nih.gov/pubmed/26661278 http://dx.doi.org/10.1371/journal.pone.0145061

Ejemplares similares

Antiproliferative Effects and Mechanisms of Liver X Receptor Ligands in Pancreatic Ductal Adenocarcinoma Cells
por: Candelaria, Nicholes R., et al.
Publicado: (2014)

Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism
por: Nguyen-Vu, Trang, et al.
Publicado: (2013)

Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation
por: Bollu, Lakshmi Reddy, et al.
Publicado: (2015)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients
por: Lima, Mariana Tavares Miranda, et al.
Publicado: (2017)

miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets
por: Klinge, Carolyn M.
Publicado: (2015)

Tamoxifen-associated vasculitis in a breast cancer patient
por: Candelaria, Myrna, et al.
Publicado: (2007)

P53 Gain-of-Function Mutants and Steroids in Ovarian Cancer Cell Metastasis
por: Candelaria, Nicholes, et al.
Publicado: (2021)

Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line
por: Won, Hye Sung, et al.
Publicado: (2016)

Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen
por: Ignatov, Atanas, et al.
Publicado: (2020)

Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
por: Lissoni, P., et al.
Publicado: (1995)

Subtype Specific Elevated Expression of Hyaluronidase-1 (HYAL-1) in Epithelial Ovarian Cancer
por: Yoffou, Paule Héléna, et al.
Publicado: (2011)

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
por: Buijs, S.M., et al.
Publicado: (2023)

Long-Term Tamoxifen Effects in the Cyclic Interaction of the Endocannabinoid and Endocrine System in the Rat Central Nervous System
por: Fonseca, Bruno M., et al.
Publicado: (2023)

ROS Generative Black Phosphorus-Tamoxifen Nanosheets for Targeted Endocrine-Sonodynamic Synergistic Breast Cancer Therapy
por: Wang, Jing, et al.
Publicado: (2023)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant)
por: Chan, Carmen Wing Han, et al.
Publicado: (2020)

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
por: Løkkegaard, Sanne, et al.
Publicado: (2021)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers
por: Addanki, Sridevi, et al.
Publicado: (2022)

Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy
por: Ramin, Cody, et al.
Publicado: (2023)

RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity
por: Barua, David, et al.
Publicado: (2023)

IARC on tamoxifen.
Publicado: (1996)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Transgenic Mice for a Tamoxifen-Induced, Conditional Expression of the Cre Recombinase in Osteoclasts
por: Sanchez-Fernandez, Maria Arantzazu, et al.
Publicado: (2012)

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases
por: MADEDDU, CLELIA, et al.
Publicado: (2014)

An Approach to Enhance Dissolution Rate of Tamoxifen Citrate
por: SreeHarsha, Nagaraja, et al.
Publicado: (2019)

Creativity as a mediator between personal accomplishment and task performance: A multigroup analysis based on gender during the COVID-19 pandemic
por: Karaboga, Tugba, et al.
Publicado: (2022)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Growth Failure and Primary Amenorrhea: Endocrine Dysfunction as a Late Presentation of Crohn's Disease
por: Muthusamy, Suganthika D, et al.
Publicado: (2023)

Tamoxifen and the Singing Voice
por: Herxheimer, Andrew
Publicado: (2005)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Use of antipsychotics with tamoxifen
por: Ghabi, H., et al.
Publicado: (2021)

Painless Legs and Moving Toes Presenting as a Tardive Phenomenon: Case Report and Review of the Literature
por: Nagarajan, Elanagan, et al.
Publicado: (2020)

Tamoxifen down-regulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance
por: Bergamaschi, Anna, et al.
Publicado: (2011)

Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy
por: Elias, D., et al.
Publicado: (2019)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy
por: Huang, Xuchen, et al.
Publicado: (2023)

Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?
por: Lee, Juhyeon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gf9hlcrs55djko68ekekfbc6n1